

Patient Associations Disclosure 2023

Novo Nordisk is committed to providing ongoing support for patient associations in therapeutic areas where we feel we can make a difference. This includes financial and non-financial support in the form of sponsorship of educational meetings, activities and charitable donations.

In 2023, Novo Nordisk supported Diabetes Ireland, European Coalition for People Living with Obesity, Global Heart Hub, Irish Coalition of People Living with Obesity, Irish Haemophilia Society and Thriveabetes.

In total, the financial value of this support was €203,588 and is detailed as follows:

- Corporate support with Diabetes Ireland in the form of a gold card membership (€20,000) and attendance at EDPAS congress (€958)
- Support to the European Coalition for People Living with Obesity in the form of a training grant (€26,200) and sponsorship (€24,250)
- Support to Global Heart Hub for the 2023 Unite Summit (€55,000)
- Support to the Irish Coalition of People Living with Obesity in the form of a grant (€23,400)
- Undirected grant to Irish Haemophilia Society towards core funding (€7,500) and a grant to support a webinar and e-zine project (€45,780)
- Grant for Thriveabetes in support of a conference (€500)

This disclosure is made in compliance with Irish Pharmaceutical Healthcare Association Code of Practice for the Pharmaceutical Industry, Annex III: Guideline for Companies on Working with Patient Associations

The Apis bull logo is a registered trademark owned by Novo Nordisk A/S

IE24NNG00051, May 2024

